LOS ANGELES, March 23, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that Linda Marbán, Ph.D., Chief Executive Officer, will present at the 3rd Annual Alliance for Regenerative Medicine (ARM) Investor Day to be held Wednesday, March 25, 2015 in New York City.

The following are specific details regarding Capricor Therapeutics, Inc.'s presentation:

Event: ARM's Regen Med Investor Day
Date:  March 25, 2015
Time:  10:35 a.m. EDT
Location:  Metropolitan Club, One East 60th Street, New York, NY 10022

A live-streaming webcast of all panels and company presentations at the Annual Regen Med Investor Day will be available at: http://www.arminvestorday.com/webcast and will be published on the ARM event website shortly after the conference.

Editor's Note: Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information, visit www.capricor.com.

CONTACT: Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance
         Robert Flamm, Ph.D.
         Russo Partners, LLC
         Christopher Hippolyte
         Russo Partners, LLC

Capricor Therapeutics logo